You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Univariate and multivariate analysis of potential prognostic factors at initial brain irradiation

From: Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era

  Univariable Analysis Multivariable Analysis
Characteristics HR (95% CI) pvalue HR (95% CI) pvalue
RPA at diagnosis of BM     
   1 1 [Reference]   1 [Reference]  
   2 1.92 (1.30-2.82) < 0.001 1.55 (1.00-2.40) 0.05
   3 5.23 (3.50-7.80) < 0.001 4.24 (2.66-6.73) < 0.001
SRS boost at initial BM     
   Yes 1 [Reference]   1 [Reference]  
   No 3.05 (1.71-5.44) < 0.001 2.94 (1.51-5.73) 0.002
Craniotomy     
   Yes 1 [Reference]   1 [Reference]  
   No 2.87 (2.15-3.84) < 0.001 2.70 (1.89-3.85) < 0.001
Number of lesions     
   1 1 [Reference]   1 [Reference]  
   2-3 1.31 (0.91-1.89) 0.139 1.19 (0.82-1.72) 0.36
   > 3 2.18 (1.66-2.88) < 0.001 1.02 (0.78-1.34) 0.88
HER2 status     
   Positive 1 [Reference]   1 [Reference]  
   Negative and Equivocal 1.74 (1.39-2.18) < 0.001 1.55 (1.09-2.20) 0.015
Chemotherapy at BM     
   Yes 1 [Reference]   1 [Reference]  
   No 2.26 (1.81-2.84) < 0.001 1.81 (1.41-2.33) < 0.001
Hormonal therapy at BM     
   Yes 1 [Reference]   1 [Reference]  
   No 1.64 < 0.001 2.22 (1.66-2.97) < 0.001
Trastuzumab at initial BM     
   Yes 1 [Reference]   1 [Reference]  
   No 1.74 (1.37-2.20) < 0.001 1.37 (0.94-2.01) 0.100
  1. Abbreviations: RPA = recursive partitioning analysis, SRS = stereotactic radiosurgery, HER2 = human epidermal growth factor receptor 2, BM = brain metastasis